Factors impacting the efficacy of the in-situ vaccine with CpG and OX40 agonist.
Alexander A PieperLeanne StunkelMildred A R FelderArika S FeilsNoah W TsarovskyJennifer BirstlerZachary S MorrisAmy K ErbeAlexander L RakhmilevichPaul M SondelPublished in: Cancer immunology, immunotherapy : CII (2023)
Increased tumor volume negatively impacts the anti-tumor capability of CpG + OX40 in-situ vaccine. The addition of checkpoint blockade augmented the efficacy of CpG + OX40 in the A20 but not B78 model. These results highlight the importance of considering multiple preclinical model conditions when assessing the efficacy of cancer immunotherapy regimens and their translation to clinical testing.